Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Neratinib: First Global Approval. Drugs (2017) 0.75

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12

Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73

Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res (2004) 3.13

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2010) 2.34

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem (2005) 1.99

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79

Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol (2010) 1.63

HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55

Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol (2012) 1.22

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20

The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol (2009) 1.17

Uterine carcinosarcoma. Curr Opin Oncol (2011) 1.13

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol (2005) 1.13

Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Hum Pathol (2013) 1.03

Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Research Program phase I study. Cancer Chemother Pharmacol (2013) 1.00

Neratinib Graduates to I-SPY 3. Cancer Discov (2014) 0.97

Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol (2013) 0.90

Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. Jpn J Clin Oncol (2012) 0.86

Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol (2014) 0.84

Epithelial to mesenchymal transition in the pathogenesis of uterine malignant mixed Müllerian tumours: the role of ubiquitin proteasome system and therapeutic opportunities. Clin Transl Oncol (2012) 0.81